Context Therapeutics Inc CNTX shares are trading lower by 26.62% to $1.02 during Thursday's session after the company reported preliminary Phase 2 data for ONA-XR metastatic breast cancer.
What Else?
Context Therapeutics says preliminary Phase 2 findings highlight a 4-month progression free survival (PFS) rate of 44%, and favorable safety and tolerability. The data were presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).
"We are pleased to be building a robust package of data supporting the safety and tolerability of ONA-XR and its potentially meaningful improvement over single agent standards of care," said Martin Lehr, CEO of Context Therapeutics.
See Also: Why NextEra Energy Shares Are Trading Lower
"We're encouraged by the improvement in preliminary PFS observed in the SMILE trial presented at SABCS this week, which is consistent with the significant improvement in PFS recently reported in the ongoing Phase 2 endometrial cancer trial. We look forward to the continued evaluation of ONA-XR across multiple ongoing breast cancer clinical trials, including the SMILE and ELONA trials."
According to data from Benzinga Pro, CNTX has a 52-week high of $7.65 and a 52-week low of $0.95.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
